EU Accelerated Assessment Tracker
Executive Summary
Janssen’s two investigational Ebola vaccines are among four new products recently granted fast-track review by the European Medicines Agency. GlaxoSmithKline and Viiv Healthcare are not disclosing the outcomes of accelerated assessment requests they have made.
You may also be interested in...
EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
ViiV Seeks Speedy EMA Review For Last-Resort HIV Drug
ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.
Myeloma BCMA Therapy In Spotlight: EMA Considers Fast Tracking GSK Filing
The European Medicines Agency is this week deciding whether GlaxoSmithKline’s planned EU marketing application for its BCMA-targeting therapy merits an accelerated assessment.